+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COVID-19 Vaccines - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 762 Pages
  • July 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5353024
After months of what seemed to be a receding pandemic supported by vaccines and adherence to new COVID appropriate protocols as the new normal, the world is witnessing the ghosts of the past rising once again. Barely months after the Indian strain called the Delta, or B.1.617.2 which was 40-60% more transmissible than Alpha and almost twice as transmissible as the original Wuhan strain of SARS-CoV-2 took over the world as a dominant strain, a new variant dubbed as Omicron (B.1.1.529) has emerged. Originally detected in South Africa in mid-November 2021, Omicron is now spreading across the globe with Asia, Europe, and North America reporting infections from this strain.

In addition to acquiring the mutations of the delta variant, the Omicron variant has over 50 mutations with 32 of them seen on its spike protein, two times higher than Delta, indicating that the virus has further adapted to the human species. Even more worrisome and unsettling is the fact that the variant also includes the vaccine-resistant alterations seen in Beta variant. The worst variant the pandemic has thrown up till date and carrying the mutations P681H and N679K, Omicron is feared to reduce vaccine effectiveness by close to 40% to 50%. There are fears that this strain is capable of outsmarting monoclonal antibodies, such as Regeneron`s treatment, since these therapies target parts of the virus that have now mutated. Currently classified as `variant of concern`, fears over the spreading Omicron have once again pushed countries across the globe to re-impose international and domestic travel restrictions. Omicron is now expected to displace the circulation Delta and other variants. It`s only a matter of time before a newer more competitive virus emerges. With Europe already battling fourth and fifth waves of infections, the new Omicron variant is bringing back ghosts of the past year. Fears are again rising over possible increase in infections, mortalities, overburdened hospitals, healthcare systems and lockdowns resulting in yet another economic nightmare. Lockdowns, travel and movement restrictions will be back once again if infection from this new strain fails to be controlled. India which is just recovering from the intense second wave with hopes of the disease reaching an endemic state, the new variant is reigniting fears of a possible third wave.

With several countries facing repeated waves of infections, the world is up against a new challenge in this war against the virus. An uphill challenge confronts governments in rapidly stepping up efforts to accelerate the pace of vaccine administration, despite numerous challenges. It`s a race against time and to successfully end the pandemic, mass vaccination drives must outpace the speed with which the coronavirus is currently mutating. Vaccine inequality is the prime reason behind the emergence of these new series of mutant strains which are more infectious, transmissible and responsible for resurgence of infection outbreaks worldwide. With the rise in vaccination rates especially in developed countries, measures designed to limit the spread of Covid-19 like mask mandates and capacity limits have been relaxed. The subsequent relaxation strengthened consumer confidence and allowed economic activity to return to normalcy. However, with the Covid-19 virus rapidly mutating, new variants have emerged in many parts of the world, posing a threat of potential future waves. Different parts of Europe are currently witnessing fourth and fifth waves of infection spread. These new variants are more deadly than the original virus, more easily transmissible and can impact the effectiveness of vaccines.
Prolonging pandemic and new mutant strains means that immunity among vaccinated population is beginning to slip, throwing the focus on booster doses. The leading vaccine makers, Pfizer-BioNTech, Moderna and AstraZeneca announced plans to pursue development of booster shots to address the emerging threat of new virus variants. The booster shot will be essential to keep the immune system to the optimum level. A number of wealthy countries like the US, Germany and Israel are considering booster shots to increase protection against Covid-19. Germany is expected to roll out booster shots to vulnerable individuals. mRNA-vaccines from Pfizer/BioNTech and Moderna will be offered as booster shots, regardless of the vaccine administered previously. In India, Bharat Biotech, the makers of Covaxin, received regulator`s approval for conducting trials for a third shot that will be administered as a booster dose. While a booster dose is typically an exact replica of the initial vaccine, it can also be tweaked. Moderna, AstraZeneca, Pfizer are working on variant-specific booster shots. Recently, Moderna announced positive initial data from its ongoing phase 2 study.

The data revealed that the booster dose increased neutralizing antibody responses against the original virus as well as B.1.351 and P.1, in previously vaccinated individuals. Studies suggest that a third dose can boost antibodies even in immunocompromised patients. The rapid pace at which new strains capable of evading antibodies are rising is throwing the focus on vaccine tweaking and researchers are already working on updating vaccines with the new spike proteins to prepare for new variants with a new version of the vaccine. This however requires additional clinical trials, more time consuming research work, and regulatory approvals. The time-to-market remains a main challenge with the process taking six to eight months before vaccines can be updated and commercialized. This time-consuming development process is a major setback when compared to the rapid rate of infection spread from new strains.

In this race against virus evolution, swift and rapid vaccinations are the need of the hour to limit the spread of mutant strains, notwithstanding the fact that vaccines themselves are contributing to virus mutations. Rapid mass vaccinations will make the mutation process and threat more manageable. It is an undeniable fact that vaccines will see a slow erosion in efficacy and effectiveness over the long-term. Therefore it is important to slow the spread of the virus by vaccinating as many people as possible at the earliest. To end the pandemic, which currently seems to have received yet another setback will require more dedicated focus on vaccine equality, international cooperation in COVID research, more transparent information transfer and alert systems on new emerging strains, waiver of IP on vaccines, and science-based swift decisions regarding travel bans. All of these are vital to prevent squandering away hard won gains achieved against the virus over the last 2 years.

Select Competitors (Total 358 Featured):

  • Moderna, Inc.
  • Pfizer Inc./BioNTech
  • AstraZeneca/University of Oxford
  • Johnson & Johnson
  • CanSino Biologics, Inc.
  • China National Pharmaceutical Group Co., Ltd. (Sinopharm)
  • Sinovac Biotech Ltd.
  • Novavax, Inc.
  • Inovio Pharmaceuticals
  • Sanofi/GlaxoSmithKline

What`s New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to the digital archives
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
MARKET OVERVIEW
  • Omicron Spreads Panic Worldwide; Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
  • TABLE 1: Time is of Essence! What We Know So Far - “Vaccine Efficiency Against New Strains is Decreasing”
  • South Africa: Omicron’s Origin Location
  • Omicron: Impact on Travel Industry
  • Countries that have Already Detected Omicron Cases
  • Steps taken by the Countries to Prevent Transmission of Omicron Variant
  • Fears of Tourism Industry
  • Industry Response to the Travel Curbs
  • Short-term Impact of Omicron on Travel
  • Financial Impact
  • Scientists Seek to Gather More Information on Omicron
  • Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
  • With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them?
  • TABLE 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness, but this Strategy is Not Within Reach for Most Countries: Number of Booster Doses Administered Per 100 People by Country as of December 2021
  • At the Dawn of 2022, We Leave Behind Millions of Deaths Due to New Strains & Once Again Stare at an Impending Catastrophe
  • Split Scenarios Unfold: The Great Vaccine Divide Emerges
  • Amid this Prolonged Pandemic, Why Should Businesses Care About Progress on Vaccinations?
  • With IMF Making an Upward Revision of Global GDP for 2021, Companies Are Bullish About an Economic Comeback Despite a Continuing Pandemic
  • TABLE 3: A Strong Yet Exceedingly Patchy & Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • TABLE 4: Easing Unemployment Levels in 2021 & 2022 Although Moderate Will Infuse Hope for Industries Reliant on Consumer Discretionary Incomes: Global Number of Unemployed People (In Million) for Years 2019, 2020, 2021, and 2022
  • Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals
  • COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster Shots
  • Are COVID-19 Boosters Going to Follow Flu Shot Pattern?
  • Covid-19 Vaccine Shortages Hit Global Supply Initiative
  • Despite US Donation, Global Delivery of COVID-19 Vaccines Remains Far Short of Target
  • Anti-Vaccine Movement Poses Significant Threat
  • TABLE 5: COVID-19 Cases Worldwide by Country: As on November 21, 2021
  • TABLE 6: COVID-19 Cases in the US by State: As on November 21, 2021
  • COVID-19 Vaccines - Global Key Competitors Percentage Market Share in 2022 (E)
THE VARIOUS COVID-19 VIRUS VARIANTS
  • Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals
  • COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster Shots
  • Are COVID-19 Boosters Going to Follow Flu Shot Pattern?
  • Covid-19 Vaccine Shortages Hit Global Supply Initiative
  • Despite US Donation, Global Delivery of COVID-19 Vaccines Remains Far Short of Target
  • Anti-Vaccine Movement Poses Significant Threat
  • COVID-19 Cases Worldwide by Country: As on November 21, 2021
  • Emergence of Delta Variant Sparks New Wave of Infections
  • Is South African Variant a Formidable Threat?
  • E484K Mutation Challenges Vaccine Developers
  • California Strain Emerges to be More Contagious and Deadly
  • Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines?
  • Less Effectiveness of AstraZeneca Vaccine Against South African Variant Leads to its Halt
  • Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
  • US Government Unveils Covid-19 Vaccine Booster Shot Plan to Maximize Vaccine Protection Against Emerging Variants
  • AstraZeneca Vaccine Effective against New Emerging Variants
  • Sinovac Vaccines Effective against Mutated Variants of Coronavirus
AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
  • COVID-19 Vaccine Approval Details
  • TABLE 7: Production Capacity by Company for Frontrunners in Millions of Doses for 2021
  • COVID-19 Vaccine Funding Details
  • Pfizer/BioNTech’s COVID-19 Vaccine Receives World’s First Authorization
  • UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
  • After UK, Pfizer’s Vaccine Gains Approval from the US and EU
  • UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
  • After UK, Pfizer’s Vaccine Gains Approval from the US and EU
  • Novartis Inks Agreement with Pfizer-BioNTech to Support Covid-19 Vaccine Production
  • After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
  • Moderna Kick-Starts Inoculation in the US
  • AstraZeneca’s Vaccine - Third Globally to Obtain Approval
  • J&J’s Single Shot Vaccination Resumes after Temporary Suspension
  • Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
  • A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
  • Johnson & Johnson's Adenovirus-based COVID-19 Vaccine vis-a-vis Moderna or Pfizer
  • Russia Commences Mass Vaccination from Mid-December, 2020
  • China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm
  • WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use
  • China Issues License for Vaccine Production to Overseas Partners
  • Brazilian Authorities Approve Sinovac’s CoronaVac
  • AstraZeneca’s Covishield and Bharat Biotech’s Covaxin Receive Emergency Use Approval in India
  • Sanofi-GSK to Offer Vaccine at a Discounted Rate
  • CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine
  • Novavax Obtains First Authorization for its COVID-19 vaccine
VARIOUS COVID-19 VACCINES UNDER CLINICAL TRIALS
  • TABLE 8: COVID-19 VACCINES UNDER DEVELOPMENT
  • TABLE 9: Vaccines in Pipeline by Technology
  • TABLE 10: Vaccine Technologies in Pre-Clinical Studies
mRNA: A NEW APPROACH TO MEDICINE
  • mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
  • RNA Technology: Benefits & Potential for Future Outbreaks
  • Key Challenges
  • mRNA Vaccines Could Vanquish COVID-19 and Cancer
  • Efforts to Target New Application Areas
MARKET DYNAMICS
  • Rise of Vaccine Passports: Key to Ease COVID-19 Restrictions & Ensure Public Safety
  • Developments Regarding Digital Certificates
  • COVID-19 Vaccine Passport: Insights & Progress
  • Why Digital Format Holds Merits?
  • What Information a Vaccine Passport Would Contain?
  • Regions/Countries Planning to Seek Vaccine Passport
  • mRNA Vaccines Offer More Protection Against Newer Variants
  • Vaccine Companies Stress on Booster Dose
  • Longer Interval between the Two Doses of Pfizer Vaccine to Boost Antibody Levels
  • Mix and Match is the New COVID-19 Vaccine Mantra
  • Long-Haul COVID-19 Holds Potential to Become a Public Health Issue
  • Vaccine Alliances Ensure Supplies for All
  • TABLE 11: Select Funding Deals for COVID-19 Vaccine R&D: 2020 & 2021
  • Licensing and Partnership Deals Worldwide Propel Vaccine Production
  • TABLE 12: COVID-19 Deals Worldwide - Jan 2020 to July 2021
GLOBAL MARKET PERSPECTIVE
  • TABLE 13: Global Percentage of Individuals Vaccinated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East and Africa Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025
  • TABLE 14: European Percentage of Individuals Vaccinated by Geographic Region - France, Germany, United Kingdom, Italy, Russia, Spain, and Rest of European Markets - Independent Analysis of Percentage of Individuals Vaccinated for 2020 through 2025
  • TABLE 15: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets
  • TABLE 16: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
  • TABLE 17: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in US$ Million for Years 2020 through 2025
  • TABLE 18: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025
VACCINES FOR KIDS
  • Kids: A Key to COVID-19 Controlling Efforts
  • US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 5-11 Years, and 12 to 15 Years Age
  • Pfizer Approves Vaccine for Kids Aged 5-11 Years
  • Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
  • Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
  • COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17 in EU
REGIONAL MARKET PERSPECTIVE
  • THE UNITED STATES
  • MARKET ANALYSIS
  • Current Vaccine Scenario
  • New Delta Variant Cases Cause Concern
  • Deceleration in Economic Activity Likely Due to Omicron Effect
  • US Recommends COVID-19 Booster Shots
  • Pfizer and Moderna’s COVID-19 Vaccine Secures US FDA’s Emergency Use Approval for Booster Shot for Vaccinated Adults
  • US FDA Authorizes Johnson & Johnson’s COVID-19 Vaccine for Booster Shot
  • Pfizer-BioNTech COVID-19 Vaccine Gets Emergency Use Nod in US for Children 5-11 Years
  • Moderna Aims to Achieve Approval for its COVID Vaccine for Children
  • Reopening of Borders & Inflow of International Travelers to US Spurs Demand for Digital Vaccine Certificates
  • Federal Health Agencies End Temporary Pause of J&J’s Covid-19 Vaccine Use
  • Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
  • The ‘Operation Warp Speed’ Program Expedites Vaccine Development
  • TABLE 19: US GOVERNMENT DEALS WITH VACCINE DEVELOPERS
  • MARKET ANALYTICS
  • TABLE 20: USA Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • TABLE 21: USA Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • CANADA
  • MARKET ANALYSIS
  • Vaccination Gathers Steam Across Canada
  • Canada Expands Approval for Pfizer-BioNTech & Moderna COVID-19 Vaccines to Cover Adolescents 12 Years & Above
  • MARKET ANALYTICS
  • Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • JAPAN
  • MARKET ANALYSIS
  • Slow Rollout of COVID-19 Vaccines in Japan
  • Japan Ropes in Armed Forces to Expedite Vaccinations
  • Slow Vaccination Rates Affect Olympics
  • Japan Looks Forward to Double Supply of COVID-19 Vaccines to Other Countries
  • Daiichi Sankyo Eyes on Booster Shots in Local Market for Impending COVID-19 Vaccine
  • Vaccine Passports
  • Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
  • Japan Pushes Shipments of Pfizer’s COVID-19 Shots to Vaccinate Elderly
  • Takeda Obtains Approval for Moderna’s Vaccine
  • AnGes Fast Tracks COVID-19 Vaccine Development Program for 2021 Rollout
  • Japan Commences Production of AstraZeneca’s Vaccine
  • VLP Therapeutics Japan Commences Trial of Replicon RNA COVID-19 Vaccine
  • MARKET ANALYTICS
  • TABLE 22: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • TABLE 23: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • CHINA
  • MARKET ANALYSIS
  • Chinese Vaccine Development Scenario
  • China Reaches Milestone of Administering over Billion Covid-19 Vaccine Doses
  • Vaccine Candidates in China
  • CoronaVac from Sinovac Obtains Emergency Use Authorization in China for Children
  • WHO Recognizes Sinopharm’s COVID-19 Jab as Effective & Safe
  • Chinese Regulator Gives Nod to COVID-19 Vaccine from Sinovac Life Sciences
  • China Approves Sinopharm’s Vaccine
  • BioNTech’s Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
  • Countries Relying on the Chinese COVID-19 Vaccines
  • Trials Indicate Neutralizing Effect of Chinese COVID-19 Vaccines on South African & UK Variants
  • MARK¬ET ANALYTICS
  • TABLE 24: Chinese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • TABLE 25: Chinese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • EUROPE
  • Covid-19 Scenario in Europe, Rise in Cases Noted
  • New Covid-19 Variants
  • Skepticism Regarding the Vaccination
  • Europe Witnesses Increase in COVID-19 Cases, Turns to Booster Doses
  • EMA Approves Use of COVID-19 Vaccine of Pfizer for Children
  • EU to Recommend 9-MonthTime Limit for COVID-19 Vaccine Validity for Travelers
  • EU Digital COVID Certificate Regulation to Aid Free Cross-Border Movement
  • EU Digital COVID Certificate: Eligibility, Process & Free Movement
  • Pfizer & Moderna Escalate Unit Price of COVID-19 Vaccines in Latest EU Contracts
  • EU Obtains 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
  • European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
  • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
  • Europe’s Horizon 2020
  • EC-AstraZeneca Settlement Deal Ends Legal Dispute over COVID-19 Vaccine Supplies
  • Johnson & Johnson to Resume Shipment of Janssen COVID-19 Vaccine to Europe
  • Apparent Side-Effects Prompt Denmark to Extend Suspension of Oxford-AstraZeneca COVID-19 Vaccine
  • MARKET ANALYSIS
  • UNITED KINGDOM
  • Vaccine Passport
  • UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
  • Vaccine Distribution Challenges
  • The UK Approves AstraZeneca’s Vaccine
  • Oxford-AstraZeneca’s COVID-19 Vaccine in the form of Nasal Spray, to be Tested Soon (March, 2021)
  • Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
  • UK’s Independent Vaccine Deals
  • GSK to Aid Production of Novavax’s COVID-19 Vaccine for Distribution within UK
  • FRANCE
  • France Embarks on Plans to Offer COVID-19 Vaccine Free to Citizens
  • France Suggests mRNA Vaccines for Second Coronavirus Shot After AstraZeneca’s First Shot
  • GERMANY
  • Germany Allows the Use of J&J Vaccine
  • SPAIN
  • Spain Prioritizes Frontline Healthcare Providers for Immunization Policy
  • Spain to Donate Vaccines to Latin America and Caribbean
  • ITALY
  • Italy Plans to Produce mRNA Vaccines Domestically
  • RUSSIA
  • Gamaleya Institute’s Sputnik V Vaccine Trials Show Promise with 92% Efficacy
  • CanSino Obtains Approval for Phase III Trial of COVID-19 Vaccine in Russia
  • NORWAY
  • Norway Bans AstraZeneca COVID-19 Vaccine
  • MARKET ANALYTICS
  • TABLE 26: European Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
  • TABLE 27: European 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2021 & 2025 Region 2021 2025
  • TABLE 28: European Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets - Independent Analysis of Sales in US$ Million for Years 2020 through 2025
  • TABLE 29: European 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2021 & 2025
  • ASIA-PACIFIC
  • MARKET ANALYSIS
  • INDIA
  • Second Wave of Covid-19 in India Attributed to Delta Variant
  • Indian Government Initiates COVID-19 Vaccination Drive
  • India Makes Notable Contribution in Production of Vaccines
  • AstraZeneca’s Covishield Receives Emergency Use Approval in India
  • Spike in New Cases Coerces India to Briefly Suspend Export of Oxford-AstraZeneca COVID-19 Vaccine
  • Bharat Biotech`s Covaxin Gets Approval
  • Bharat Biotech Obtains Government Financial Backing to Ramp up Production of Covaxin
  • Panacea Biotec Obtains DCGI`s Nod for Manufacturing Sputnik V vaccine
  • Bharat Biotech & SII on Capacity Expansion Mode
  • Trial Indicates Decent Efficacy of Covaxin against B.1.617 Variant of COVID-19
  • IIL Partners with Bharat Biotech to Produce Active Drug Substance for Covaxin
  • Johnson & Johnson’s Covid-19 vaccine, Produced by Biological E, Ready for Export
  • Serum Institute Obtains Approval for Novavax Vaccine Trial in 7-11 Age Group
  • Increasing Commitments of SII and Novavax
  • Dr Reddy`s Rolls out Sputnik V Covid-19 Vaccine in India
  • DCGI Yet to Approve COVAXIN for Children
  • DCGI’s Approval Mandatory for the Covaxin to be Administered for Children
  • Sanofi, GSK Obtains Approval to Conduct Phase 3 trial of their Covid-19 vaccine in India
  • Zydus Vaccine Approved for Kids
  • AUSTRALIA
  • Australia to Invest on Novel Coronavirus Vaccines for Wider Region
  • NEW ZEALAND
  • New Zealand Acquires Ultra-Cold Freezers to Store Pfizer’s COVID-19 Vaccine
  • SOUTH KOREA
  • With the Spread of Delta Plus Variant, Fresh Covid Cases Witness a Sharp Increase
  • South Korea Extends its Vaccination Programme to the Workers of Electronics and Chip Manufacturing Industries
  • J&J Covid-19 Vaccine Receives Approval in South Korea
  • INDONESIA
  • Indonesia Negotiates Additional COVID-19 Vaccines from China and GAVI
  • Indonesia Gets First Consignment of COVID-19 Vaccine from China’s Sinovac
  • Chinese Vaccine Sinovac Allowed for Use in Sri Lanka and Bangladesh but restricted in Malaysia
  • BANGLADESH
  • Serum Institute of India to Offer 3 Crore Doses of COVID-19 Vaccine to Bangladesh
  • MYANMAR
  • China Meets Myanmar’s Requirements
  • MARKET ANALYTICS
  • TABLE 30: Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - India, and Rest of Asia-Pacific Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
  • TABLE 31: Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for India, and Rest of Asia-Pacific Markets for Years 2021 & 2025
  • TABLE 32: Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - India, and Rest of Asia-Pacific Markets - Independent Analysis of Dollar Sales in US$ Million for Years 2020 through 2025
  • TABLE 33: Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for India, and Rest of Asia-Pacific Markets for Years 2021 & 2025
  • THE MIDDLE EAST
  • MARKET ANALYSIS
  • BAHRAIN
  • Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer’s Vaccine
  • Sinopharm’s Vaccine Doses Reach Bahrain
  • COVID-19 Vaccine Production in the UAE
  • SAUDI ARABIA
  • IRAN
  • Iran Procures Vaccine Doses
  • AFGHANISTAN
  • Afghanistan to Procure COVID-19 Vaccines
  • TURKEY
  • COVID-19 Vaccines in Turkey
  • ISRAEL
  • Israel Reimposes Restrictions
  • COVID-19 Vaccines for Israel
  • SYRIA
  • Syria Obtains AstraZeneca Vaccines, the first for the Country
  • MARKET ANALYTICS
  • TABLE 34: The Middle East Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • TABLE 35: The Middle East Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • AFRICA
  • MARKET ANALYSIS
  • UNICEF Enters into Agreement with Janssen Pharmaceutica for Supply of Vaccine to African Union
  • Relief for Countries in Africa that Finally Receive Vaccine Shipment as third wave Creates Havoc
  • Takeaways from Covid-19 Vaccine Program in Africa
  • SOUTH AFRICA
  • Approach of South Africa towards Covid-19 Vaccination Program
  • New Virus Variant in South Africa Creates a Challenge
  • South Africa Halts AstraZeneca’s Vaccination
  • Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
  • South Africa: The First Country in Africa to Start Vaccine Clinical Trial
  • South Africa to Resume J&J Jab Vaccination
  • Aspen to Manufacture Johnson & Johnson’s COVID-19 Vaccine in South Africa
  • China to Deliver Potential COVID-19 Vaccine to Africa for Free
  • CEPI Identifies Biovac Institute as Potential Manufacturer in South Africa
  • EGYPT
  • MARKET ANALYTICS
  • TABLE 36: African Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in Million Doses for the Years 2020 through 2025
  • TABLE 37: African Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025
  • LATIN AMERICA
  • MARKET ANALYSIS
  • Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
  • BRAZIL
  • Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
  • Brazilian Town Serrana Beats COVID-19 with China`s Sinovac Vaccine
  • Brazil, Turkey Announce Vaccination Plans for Chinese Vaccine
  • GSK to Aid Production of Novavax’s COVID-19 Vaccine for Distribution within UK
  • Brazil Blocks Import of Russian Sputnik V COVID-19 Vaccine over Efficacy & Safety Concerns
  • Covaxin Clinical Trial’s Stopped in Brazil but Supply Continued in India
  • MEXICO
  • Mexico’s Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
  • Tulane University, Children’s Hospital Launch Moderna COVID-19 Vaccine trial for Childre
  • ARGENTINA
  • Argentina Secures 22 Million Doses of AstraZeneca’s COVID-19 Vaccine
  • CHILE AND PERU
  • Chile, Peru Approve Clinical Trials for AstraZeneca’s COVID-19 Vaccine
  • Chile Struggles with Escalating Cases of COVID-19 despite Massive Rollout of Vaccine
  • CanSinoBIO Secures Emergency Use Authorization for COVID-19 Vaccine in Chile
  • MARKET ANALYTICS
  • TABLE 38: Latin American Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico, and Rest of Latin American Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025
  • TABLE 39: Latin American 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for Brazil, Mexico, and Rest of Latin American Markets for Years 2021 & 2025
  • TABLE 40: Latin American Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico, and Rest of Latin American Markets - Independent Analysis of Dollar Sales in US$ Million for Years 2020 through 2025
  • TABLE 41: Latin American 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil, Mexico, and Rest of Latin American Markets for Years 2021 & 2025
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
FOCUS ON THE FRONTRUNNERS
  • Moderna, Inc. (USA)
  • Pfizer Inc./BioNTech (US/Germany)
  • AstraZeneca/University of Oxford (The UK)
  • Johnson & Johnson (USA)
  • CanSino Biologics, Inc. (China)
  • China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
  • Sinovac Biotech Ltd. (China)
  • Novavax, Inc. (USA)
  • Inovio Pharmaceuticals (USA)
  • Sanofi/GlaxoSmithKline (France/UK)
INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES
  • Fair Distribution of COVID-19 Vaccine
  • Vaccine Nationalism Hampers Equitable Distribution of Vaccines
  • COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine
  • COVAX Inks Additional Deals for Global Rollout of COVID-19 Vaccines
  • African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines
  • COVAX Advance Market Commitment (AMC)
  • World Economic Forum to Push COVID-19 Vaccine Production Capability
  • Pushing Manufacturing Capacity to Fulfil Global Demand
  • Technology Transfer and Other Payments
KEY VACCINE TECHNOLOGY PLATFORMS
  • Inactivated Vaccines
  • Inactivated Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
  • Protein-Subunit Vaccines
  • Protein-Subunit Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
  • Non-Replicating Viral-Vector
  • Non-Replicating Viral Vector Vaccine in Preclinical Development: As on Nov 19, 2021
  • Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on Nov 19, 2021
  • Nucleic Acid Vaccines
  • RNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
  • DNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
  • Replicating Bacteria Vector
  • Live Attenuated Vaccines (LAVs)
  • Live Attenuated Virus Candidate in Preclinical Studies: As on Nov 19, 2021
  • Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on Nov 19, 2021
  • Virus-like Particle Vaccines
  • Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on July 27, 2021
WORLD COVID-19 VACCINE BRANDSSELECT CORPORATE DEVELOPMENTS IN THE COVID-19 VACCINE MARKET: 2021
IV. COMPETITION
  • Total Companies Profiled: 358

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Moderna, Inc.
  • Pfizer Inc./BioNTech
  • AstraZeneca/University of Oxford
  • Johnson & Johnson
  • CanSino Biologics, Inc.
  • China National Pharmaceutical Group Co., Ltd. (Sinopharm)
  • Sinovac Biotech Ltd.
  • Novavax, Inc.
  • Inovio Pharmaceuticals
  • Sanofi/GlaxoSmithKline